Non-Adherence to medications is a common problem in clinical practice especially among patients with asymptomatic chronic conditions like type II diabetes and hypercholesterolemia in whom some 50% of patients are non-adherent. The costs of poor adherence to medications have been estimated to approach $100 billion dollars a year and are the result of adverse outcomes such as hospitalization, the development of complications, disease progression, premature disability or death. Non-Adherence is the result of a complex interaction among the social environment, the patient and the health providers. Adherence to medications is not routinely measured in clinical practice and a gold standard that can be easily implemented even for research purposes does not exist. Yet, the use of claims data to measure adherence has been shown useful and, given the relatively small costs associated with its use, its implementation in routine clinical practice appears both feasible and sustainable. However, more information is needed on the validity of the method and on the consequences of making adherence information available to both patients and physicians. Using The Chronic Care model as a theoretical framework, we propose a two-phase study. In Phase I, claims data will be used to identify diabetic patients receiving pharmacological treatment for both diabetes and hypercholesterolemia and to measure their A to medications prescribed for the two conditions. The association between adherence indices and intermediate outcomes (glycosylated hemoglobin and cholesterol levels) will be estimated. In Phase II, qualitative (focus groups) and quantitative methods (telephone and mail surveys) will be used to examine patients' attitudes, beliefs, barriers, relationship with providers, and stages of change towards adherence and towards the introduction of adherence information in clinical practice in conjunction with the Health Belief and Stages of Change Models as explanatory theories. The study will help clarify the association between adherence and clinical outcomes as well as to estimate the predictive and convergent validity of prescription claims data as a method of measuring adherence to medications. Finally, we will explore intrinsic factors at the patient level related to adherence, and patient and provider preferences and attitudes towards the use of adherence information in routine clinical practice. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK064695-03
Application #
6927182
Study Section
Social Sciences, Nursing, Epidemiology and Methods 4 (SNEM)
Program Officer
Garfield, Sanford A
Project Start
2003-08-05
Project End
2006-07-31
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
3
Fiscal Year
2005
Total Cost
$238,810
Indirect Cost
Name
Henry Ford Health System
Department
Type
Schools of Medicine
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Lanfear, David E; Gibbs, Joseph J; Li, Jia et al. (2017) Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. JACC Heart Fail 5:823-832
Zhou, Kaixin; Yee, Sook Wah; Seiser, Eric L et al. (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055-1059
Wells, Karen E; Cajigal, Sonia; Peterson, Edward L et al. (2016) Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. J Allergy Clin Immunol 137:1364-1369.e2
Pladevall, Manel; Divine, George; Wells, Karen E et al. (2015) A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educ 41:136-46
Yessayan, L; Shafiq, A; Peterson, E et al. (2015) Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation. Transplant Proc 47:2968-72
El-Refai, Mostafa; Hrobowski, Tara; Peterson, Edward L et al. (2015) Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure. J Cardiovasc Med (Hagerstown) 16:591-6
Velez, Mauricio; Peterson, Edward L; Wells, Karen et al. (2015) Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 21:2-8
Padhukasahasram, Badri; Reddy, Chandan K; Levin, Albert M et al. (2015) Powerful Tests for Multi-Marker Association Analysis Using Ensemble Learning. PLoS One 10:e0143489
Lanfear, David E; Li, Jia; Abbas, Raza et al. (2015) Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients. J Cardiovasc Transl Res 8:545-53
Bunyavanich, Supinda; Schadt, Eric E; Himes, Blanca E et al. (2014) Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis. BMC Med Genomics 7:48

Showing the most recent 10 out of 49 publications